CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the CollPlant Biotechnologies investor conference call to discuss financial results for the full-year 2022 and corporate updates. A question-and-answer ...

● attract and retain skilled personnel; ● create additional infrastructure to support our operations as a public company; and ● experience any delays or encounter issues with any of the above. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of secu ...

Exhibit 99.1 Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen ● Additional large-animal study planned in H2 2023 to further 3D bioprinted regenerative breast implant program ● Conference call to be held on March 29, 2023 at 10:00 am U.S. ET; Dial-in information herein Rehovot, Israel, March 29, ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results ● Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan ● Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv University and SHEBA Hospital ● 3D bioprinted regenerative breast implant program on track for Q1 2023 readout of large animal ...

Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 TABLE OF CONTENTS | --- | --- | |-----------------------------------------------------------------------------------|----------------| | CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: | Page | | Condensed Consolidated Balance Sheets | F-2 - F-3 | | Condensed Consolidated Statements of C ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results ● Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 ● Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen ● Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 ● Strong balance sheet with $43.3 million cash position, as of December 31, 2021 R ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results ● Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 ● Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen ● Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 ● Strong balance sheet with $43.3 million cash position, as of December 31, 2021 R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ev ...

ef CollPlant Overview Pioneering Regenerative Medicine September 2021 Safe harbor statement 2 Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission File No.: 001-38370 CollPlant Biotechnologies Ltd. (Exact name of registrant as specified in its charter) Translation of registrant's name into English: Not applicable State of Israel 4 Oppenheimer, Weizmann Science Park Rehovot 7670104 , Israel Tel: +972 73 232 5600 (Jurisdiction of incorpo ...